ABSTRACT-Airway hyperresponsiveness (AHR) is a critical component in bronchial asthma, but the underlying mechanisms remain to be disclosed. Our present studies were performed to establish a new good experimental animal model of AHR. Male Wistar rats actively sensitized with DNP-Ascaris antigen (DNP Asc) were challenged by inhaling DNP-Asc 8 days after the first immunization (single antigenic challenge). Another sensitization group received 3 challenges every 48 hr (repeated antigenic challenge). The airway responsiveness to inhalations of acetylcholine (ACh) and neurokinin A (NKA) were determined under anesthesia. The airway microvascular leakage was also determined with Evans blue (E.B.). At 24 hr after the single antigen challenge, the airway responsiveness to ACh and NKA were slightly enhanced, and the E.B. exudation was increased in the main bronchus. In contrast, the airway responsiveness to ACh and NKA and the E.B. exudation in the main bronchus were much more markedly enhanced 24 hr after the repeated antigenic challenge. The isolated main bronchial strip from the challenged rats had obtained AHR towards ACh and serotonin. These findings suggest that repeated antigenic challenge causes a distinct AHR, both in vivo and in vitro, and that the airway inflammation may be closely related to pathogenesis of AHR.
Nonspecific airway hyperresponsiveness (AHR) is a common feature in individuals with allergic bronchial asthma (1, 2). In allergic asthma, inhalation of allergen causes not only an immediate and reversible bronchocon striction but also AHR to stimuli such as histamine and acetylcholine (ACh). The importance of the increased responsiveness in the pathogenesis of asthma has been sug gested by its correlation with the severity of this disease (1, 3). It is thus very important to understand the under lying mechanisms of AHR for the sake of asthma thera py.
To understand the mechanisms of AHR, various animal models have been developed. O'Byrne et al. report ed that prostaglandin F2a (4), leukotriene B4 (5) and ozone (6) induced AHR to ACh in normal dogs. However, it is unlikely that these dog models resemble human allergic asthma because these animals were not made allergic. A frequently used animal model is guinea pigs that have been sensitized with ovalbumin (OA) together with some adjuvant (7, 8) . However, this species has been consi dered to be immunologically different from humans with regard to the mechanisms of allergic asthma involving antibody (9).
Because allergic bronchoconstriction in rats has certain features in common with human allergic asthma, rats show good potential as an allergic asthmatic animal model (10, 11) . It has been demonstrated that the im munoglobulin E (IgE) antibody was easily generated when rats were sensitized with DNP-Ascaris antigen (12). The sensitized rats also exhibit early and late asthmatic responses to antigen inhalation (13) . In the present study, to investigate the underlying mechanisms of AHR, we first tried to develop a new animal model of AHR by utiliz ing this species. The relationship between AHR and air way inflammation in our rat model was also examined.
MATERIALS AND METHODS

Antigen challenge
Specific-pathogen-free male Wistar rats weighing 230-314 g (6-8 weeks of age), purchased from Charles River Japan, Inc. were housed under standard laboratory conditions with free access to food and water. Animals were sensitized with 2,4-dinitrophenylated Ascaris suum extract (DNP-Asc, 2 mg protein, s.c.) together with killed Bordetella pertussis (2 x 1010) as an adjuvant and were boosted by DNP-Asc (0.5 mg protein, i.m.) 5 days later, according to the method of Tada and Okumura (12). Eight days after the first immunization, the rats were challenged by inhaling DNP-Asc (6 mg protein/ml, 5 6 ml) with an ultrasonic nebulizer (TUR-3000, Nihon Kohden, Tokyo) for 20 min under the unanesthetized condition in a plexiglass box (300 x 200 mm, height: 150 mm). These animals were designated as the single challenge group and used for experiments 24 hr after the antigenic challenge. Another group of animals called the repeated challenge group received 3 times antigenic challenge every 48 hr by the same challenge method as described above. They were used 12, 24, 48 or 72 hr after the last antigenic challenge. Control rats received the same immunization, but inhaled saline instead of the DNP-Asc challenge dose.
In vivo determination of airway responsiveness
The determination of airway responsiveness to ACh or neurokinin A (NKA) was measured 24 hr after the last antigenic challenge. Rats were anesthetized with urethane (2 g/kg, i.p.), placed in the supine position and ventilated artificially through a tracheal cannula at a frequency of 70 breaths/min. Respiratory volume was adjusted at the beginning of the experiment so that ventilation overflow (VO) would be 0.5 ml in each rat. Spontaneous respira tion was stopped by an injection of pancuronium bromide (1 mg/kg, i.v.). The bronchomotor tone was measured by the modified Konzett-Rossler method (14) . The lung was inflated at a fixed volume of air under a con stant pressure (5 cmH2O), and VO was continuously recorded with a combination of a pneumotachograph (TP-602T, Nihon Kohden) and an integrator (EI-601 G, Nihon Kohden). Systemic blood pressure was monitored with a pressure transducer (DX-300, Nihon Kohden) from a cannula inserted into the left carotid artery, and heart rate was measured with a tachometer (AT-601G, Nihon Kohden) with the systemic blood pressure as the trigger. All the above parameters were recorded on a polygraph (RM-6000, Nihon Kohden).
The rats were subjected to cumulative inhalation of ACh (0.001 0.03 %) or NKA (0.0001 0.01 %), each for 3 min, by aerosolizing the solution contained in a special ly devised plastic cylindrical chamber (capacity: 25 ml) that was introduced in an ultrasonic nebulizer (TUR 3200, Nihon Kohden). The ultrasonic nebulizer with the plastic chamber was placed into the respiratory circuit so that the aerosolized mist was inhaled into the airway each time of ventilation.
In some experiments (at 8 days after the first immuni zation in the single challenge group and at the third challenge in the repeated challenge group), the antigenic challenge was performed under anesthesia by inhaling DNP-Asc for 20 min through the tracheal cannula, and the DNP-Asc-induced immediate type of bronchoconstric tion was compared between the two groups.
In vitro determination of airway responsiveness Twenty-four hours after the last antigenic challenge, the rats were sacrificed by a blow to the head and exsangui nated. The trachea and bronchus were rapidly removed, cleaned of adhering connective tissues and cut open lon gitudinally along its ventral surface. About a 5-mm length of the tracheal strip was isolated 5 mm under the larynx (5 6 cartilages), and the left bronchial strip was also iso lated (about 5-mm length, 8-9 cartilages). Each tissue strip was then suspended in a 10-ml organ bath, at a rest ing tension of 1 g. The isometrical contraction of each strip was measured with a force-displacement transducer (TB-612T, Nihon Kohden) and recorded on a polygraph (RM-85, Nihon Kohden). The organ bath contained modified Krebs-Henseleit solution with the following com position: 118 mM NaCI, 4.7 mM KCI, 2.5 mM CaC12, 1.2 mM MgSO4i 25.0 mM NaHCO3, 1.2 mM KH2PO4 and 10.0 mM glucose. The buffer solution was main tained at 371C and oxygenated with 95016 02-5% C02 During an equilibration period in the organ bath, the tis sues were washed three to four times at 15 to 20 min inter vals and equilibrated slowly to a baseline tension of 1 g for both strips. A further period of 15 min was required for tissue stabilization.
The concentration-response curves for ACh and serotonin (5-HT) were constructed cu mulatively, with a concentration range of 10-7-10-4M. A higher concentration of agonist was successively added after attainment of a plateau response to the previous con centration. Under these conditions, reproducible concen tration-response curves were obtained on the same tissue strip.
In our in vitro experiments, NKA (10-8-10-6 M) had no effect on most of the tracheal and main bronchial strips, so that we used 5-HT instead of NKA as a pharma cological stimulant in the in vitro experiments.
Determination of airway microvascular leakage
At twenty-four hour or other time points after the last antigenic challenge, the rats were anesthetized with ure thane (2 g/kg, i.p.). Airway vascular permeability was quantified by the extravasation of Evans blue dye (E.B.) using a modification of the method of Evans et al. (15) , which correlates well with extravasation of radiolabeled albumin (16) . E.B. (30 mg/ml in saline, filtered with paper filter), 30 mg/kg, and heparin (600 U/kg) were ad ministered by i.v.-injection. Twenty minutes later, the animals were exsanguinated from the abdominal aorta, and then the thorax was opened and a blunt-ended 13 gauge needle was passed through the right ventricle into the pulmonary artery. The pulmonary veins were incised to allow the outflow of perfusate, and the airways and lungs were perfused with 20 30 ml of 1 % paraformalde hyde in citrate-buffered saline (pH 3.5) to remove intravas cular dye and to fix the tissues. After then, the trachea, main bronchus and lungs were removed and their wet weights were measured. E.B. was extracted by incubating tissues in 1 ml (trachea and main bronchus) or 3 ml (lungs) of 100% form amide at 60V for 24 hr, and its concentration was deter mined by light absorbance at 620 nm (U-2000 spectro photometer, Hitachi) and by interpolation on a stand ard curve of E.B. concentrations (3.125-50,ug/ml). E.B. content from each sample was expressed as nanograms per milligram wet weight of tissue.
Passive cutaneous anaphylaxis (PCA)
To measure PCA titer, the blood specimens were ob tained from the heart at 8 and 12 days after the first im munization and at 12, 24, 48 and 72 hr after the last anti genic challenge. The blood specimens were immediately ice-cooled for 10 min and then centrifuged (3000 rpm, 41C for 10 min). The sera obtained were stored at -35 C until used.
Serial dilutions (4-512) of the serum obtained from in dividual bleedings were injected intradermally in 0.05 ml quantities into the shaved backs of normal rats. After 48 hr, the rats were i.v.-injected with DNP-Asc (2 mg pro tein/200 g body weight) with 1 % E.B. (0.5 ml/200 g body weight) into the tail veins. After 30 min, they were exsan guinated from the cervical aorta, and the skin was reflect ed for measurement of the extent of extravasation of the dye. When the diameter was > 5 mm, the dilution was de termined to be the end point.
Histological examination
For histological examination, 5 to 7 rats of each group (control, single challenge and repeated challenge groups) were used. These animals were exsanguinated from the ab dominal aorta, and the lower airway was removed after opening the thorax. Then the tissue was gently washed with normal saline and fixed in neutral formalin solution. The trachea, main bronchus and lung were cut into 3 5 mm chips, and each of the chips was embedded in paraffin by a standard technique. The paraffin sections were stained with hematoxylin and eosin.
Drugs
The following drugs were used: acetylcholine chloride (purchased from Daiichi Pharmaceutical Co., Ltd., Tokyo); NKA (from Peptide Institute, Inc., Osaka); pan curonium bromide (from Sankyo Pharmaceutical Co., Ltd., Tokyo); serotonin (5-hydroxytryptamine hydrochlo ride) and urethane (ethyl carbamate) (from Sigma Chemi cal Co., Ltd., St. Louis, USA). Evans blue was obtained from Merck Co., Ltd. (New Jersey, USA). Heparin sodi um was from Kodama Co., Ltd. (Tokyo).
For the in vivo studies, ACh, NKA and pancuronium bromide were freshly made just before use. Just before use in the in vitro studies, fresh solutions of ACh and serotonin were made in Krebs-Henseleit solution (compo sition described above). Urethane and Evans blue were dissolved in saline and stocked at room temperature. Heparin solution was diluted freshly in saline each day.
Statistical analyses
All the data except for the PCA titers are expressed as the mean with S.E. Statistical significance of difference was determined by Student's t-test for unpaired data or the Cochran-Cox test. The potency ratio of the in vivo bronchoconstrictor response to ACh or NKA was calculat ed by parallel line assay. The PCA titer of each group is expressed as the mean and its statistical significance was determined by the Wilcoxon rank-sum test. Table 1 . The maximal increase in ventilation overflow (d VOmax) and the time for reaching VOmax (Tmax) during DNP-Asc (6 mg pro tein/ml) challenge for 20 min under anesthesia AVOmax and Tma, were expressed as the mean ±S.E. First challenge: 8 days after the first immunization (matched for the antigenic challenge of the single challenge group). Last challenge: 12 days after the first immunization (matched for the last antigenic challenge of the repeated challenge group). ns: no significant difference from the first challenge group.
RESULTS
Comparison of antigen induced-bronchoconstrictions be tween single and repeated challenge groups Eight days after the first immunization, inhalation of aerosolized DNP-Asc (6 mg protein/ml, 20 min) to sensi tized rats under anesthesia (First challenge) induced an in crease in ventilation overflow (VO as an index of bron choconstriction) (Table 1) . A similar, but slightly strong er, response was confirmed at the last antigenic challenge in the repeated challenge group (Last challenge). However, there was no significant difference between the groups in the maximal increase in VO (VOm nor the time for reaching VOmax (Tmax) during inhalation of DNP Asc. Change in airway responsiveness after single antigen challenge Inhalation of four cumulative aerosols of ACh (0.001, 0.003, 0.01 and 0.03%, each for 3 min) to anesthetized control rats induced a concentration-related bronchocon striction (Fig. la) . When the animals were challenged only once with DNP-Asc, the concentration-response curve to ACh was shifted to the left 3.2-fold in terms of the concentration ratio, 24 hr after the challenge. The air way responsiveness to ACh was significantly enhanced at concentrations of 0.001 and 0.003% (P<0.05). Similar results were obtained with NKA (0.0001, 0.0003, 0.001, 0.003 and 0.01 %, each for 3 min) (Fig. Ib) ; the concentra tion-response curve was shifted to the left (sixfold) 24 hr after the single antigenic challenge. The airway responsive ness to NKA was significantly enhanced at concentrations of 0.0003 and 0.00101o (P<0.05).
Change in airway responsiveness after repeated antigen challenge
The airway responsiveness to inhaled ACh was much more markedly increased 24 hr after the repeated anti genic challenge. Figure lc shows the concentration-response curve for inhaling ACh 24 hr after the last antigenic challenge. In the repeated challenge group, a dramatic leftward shift of the concentration-response curve (12.0 times; its 95% confidence interval: 6.1 63.9, P < 0.05) was observed, as compared with the single challenge group. Similar results were obtained with comulative inhalation of NKA; the concentration-response curve was shifted to the left (12.4 fold; its 95% confidence interval: 9.0-19.5, P<0.05) 24 hr after the last antigenic challenge (Fig. Id) .
The AHR to ACh observed 24 hr after the last anti genic challenge was completely blocked by atropine (1 mg/kg, i.v.). Time course of AHR to ACh after repeated antigen challenge Figure 2 shows the time course of airway responsive ness to ACh after the last DNP-Asc challenge in the repeated challenge group. The airway responsiveness to ACh was stronger in the following order, 24 hr > 12 hr > 48 hr > 72 hr after the last DNP-Asc challenge. The most severe airway hyperresponsiveness was thus shown at 24 hr after the last antigenic challenge. At 72 hr after the last antigenic challenge, however, the airway respon siveness almost recovered to the control level.
The antibody titer was measured by 48-hr passive cutaneous anaphylaxis (PCA) at 8 and 12 days after the first immunization and at 12, 24, 48 and 72 hr after the last antigenic challenge (Table 2 ). There was no signifi cant difference in PCA titers among the groups, except that the titer at 72 hr after the last challenge was sig nificantly lower than that at 24 hr (P <0.05). Change in the in vitro airway tissue responsiveness after repeated antigen challenge ACh elicited a concentration-dependent contractile response of the rat tracheal and bronchial strips (Fig. 3, a  and c) . In the control (saline inhalation) group, the con tractile response elicited by 10-4 M ACh was 1.11 ±0.06 g (n = 8) in the trachea and 0.3 8 ± 0.05 g (n = 8) in the bron chus (Fig. 3, a and c) . As compared with the control group, the contractile response of the bronchial strips was significantly enhanced 24 hr after the last antigenic challenge in the repeated challenge group; the contractile response elicited by 10-4 M ACh was 1.00±0.08 g (n=6, P<0.001). No change in responsiveness of the tracheal strips (n=6) was, however, observed even after the anti genic challenge.
5-HT elicited relatively small contractile responses of the rat tracheal and bronchial strips (Fig. 3, b and d) . In the control group, the maximal contractile response elicit ed by 10-'M 5-HT was 0.07-±:0.03g (n=5) in the tracheal strips and that elicited by 3 x 10-5 M 5-HT in the bronchial strips was 0.05±0.01 g (n=5) (Fig. 3, b and d) . The contractile responses caused by 5-HT were also sig nificantly enhanced in the bronchial strips which were ex cised 24 hr after the last antigenic challenge; the maximal contractile response elicited by 3 x 10-5 M 5-HT was 0.19±0.04 g (n=5, P <0.05).
Change in microvascular leakage after antigen challenge Figure 4 shows E.B. extravasation in the tracheal, main bronchial and lung tissues at 24 hr after the single challenge and at 12 or 24 hr after the last challenge of the 3 times repeated challenge. E.B. extravasation in the trachea was significantly increased at 24 hr after the repeated challenge (P<0.05 vs. control). In the main bronchus, E.B. extravasation was significantly increased at 24 hr after the single challenge (P<0.01 vs. control), but a more marked increase in E.B. extravasation was observed at 12 and 24 hr after the repeated challenge (P<0.001 and P < 0.01 vs. single challenge group, respec tively). On the other hand, E.B. extravasation in the lungs was increased in none of the challenge groups.
The E.B. extravasations in the tracheal (12.16±4.15 ng/mg tissue, n = 5), main bronchial (11.65 ± 2.00 ng/mg tissue, n=5) and lung (3.62±0.24 ng/mg tissue, n=5) tissues 48 hr after the last antigenic challenge were not significantly different from the respective control value (data not shown). Histological analysis Some histological studies were performed on the vari ous tissues. Figures 5 and 6 show the main bronchial tis sues stained with hematoxylin and eosin from the control and repeatedly challenged rats, respectively. Twenty-four hours after the repeated challenge, mast cell and inflam matory cell (monocytes, lymphocytes, polynuclear cells, etc.) infiltration was markedly increased. The infiltration of these cells was more severe in the repeated challenge group (Fig. 6 ) than in the single challenge group (data not shown). In the repeated challenge group, the main bron chus was affected more severely than the trachea and lungs. Furthermore, epithelial cells were moderately changed (e.g., increased and hypertrophied goblet cells), especially in the main bronchus. 
DISCUSSION
Our results demonstrated that repeated antigenic challenge caused a distinct AHR (enhanced airway respon siveness to inhaled ACh and NKA) and airway inflamma tion (increased airway microvascular leakage and histo logical change) in actively sensitized rats. The peak of AHR to ACh was shown at 24 hr after the last antigenic challenge. At this time point, it was found that the AHR could be obtained even in the in vitro level, that is, in bronchial tissue. A severe airway inflammation was demonstrated at 12 24 hr after the last antigenic challenge in the bronchus. ACh and NKA were used to determine the in vivo air way responsiveness. ACh was frequently used for the test of AHR in clinical diagnosis. NKA, one of the putative neurotransmitters of the excitatory non-adrenergic, non cholinergic nervous system, is a potent bronchoconstric tor agent (17) . In the present study, the AHR to ACh was completely blocked by atropine, indicating that there ex isted a muscarinic hyperreactivity. However, this is not a specific hyperreactive response because the airway respon siveness to NKA was also enhanced.
When rats were sensitized with DNP-Asc antigen ac cording to the method of Tada and Okumura (12), the 48 hr PCA titer (IgE antibodies are involved) is known to reach the maximal level at 8 days after the first immuniza tion. Thus, at first, this time point was selected to carry out the antigenic challenge (to elicit the immediate asthmatic response) under unanesthesia. The objective symptoms observed were analogous to those of allergic bronchial asthma (e.g., abnormality of breaths) in all the animals used.
Presently, the airway responsiveness to ACh and NKA were significantly enhanced at 24 hr after the single challenge, but the enhanced level was not so potent. Generally, with regard to allergic bronchial asthmatics, they are continually exposed to a certain antigen (e.g., house dust). Recently, with this view in mind, repeated an tigenic challenge to sensitized animals has been attempted by some investigators (18) (19) (20) . On the other hand, Bellofiore and Martin (18) reported that the gradual desen sitization to OA antigen was elicited after 6 times repeat ed challenge in Brown-Norway rats. In our experiments, the antigenic challenge protocol of 3 times repeated challenge every 48 hr successfully produced a marked in creased responsiveness to ACh and NKA 24 hr after the last challenge of the repeated challenge.
Twenty-four hours after the last antigenic challenge, the in vitro airway responsiveness to ACh and 5-HT were also enhanced in the main bronchus but not in the tra chea. The airway microvascular leakage was more mark edly increased in the bronchus than in the trachea. Fur thermore, in our histological study, infiltration of inflam matory cells was much more severe in the bronchus than in the trachea. It has been thought that airway inflamma tion is induced by some chemical mediators such as prostaglandins, leukotrienes (LTs), thromboxane A2 (TXA2), and platelet-activating factor (PAF) derived from the inflammatory cells (e.g., mast cells, neutrophils, eosinophils), which results in AHR (21, 22) . Additional ly, neuropeptides which are contained in the sensory nerve endings (23) , may be also involved in the occurrence of airway inflammation. The difference in the present results between the tracheal and main bronchial regions is not now explainable. It was, however, possible that be cause the distribution of these inflammatory cells might be more abundant in the main bronchus, the chemotaxis of these inflammatory cells might be caused more strongly in the main bronchus than in the trachea. Another pos sibility is that the neural control of the main bronchus might be essentially different from that of the trachea (e.g., the regional difference of responsiveness to ACh, carbachol (24) and LTC4 (25) was reported in rats and ex citatory nonadrenergic, noncholinergic innervation is much abundant in the bronchial region than in the tracheal region in guinea pigs (26) ). Furthermore, it is pos sible that there may be a difference in physical adhesion of the antigen to the airway lumenal surface as compared to its adhesion in the bronchus. This regional difference in the airway inflammation was likely to reflect the regional difference in the AHR in the in vitro experiments also.
It has been reported that an antigenic challenge to sensi tized guinea pigs (27) and rabbits (28) resulted in an air way smooth muscle hyperresponsiveness in vitro. These animals also obtained AHR in the in vivo level (7, 28). These findings therefore suggest that the increased airway smooth muscle responsiveness itself may be reflected in the in vivo AHR. Our result that the responsiveness to ACh and 5-HT were enhanced in the bronchial tissue in vitro supports this speculation. However, attempts to demonstrate hyperresponsiveness of isolated airway smooth muscle strips from asthmatics in vitro have so far produced varied results. There seems to be little or no in crease in the sensitivity of airway strips from asthmatics (obtained post-mortem) (29, 30) . In contrast, some stud ies, particularly those using surgical specimens, have described a substantial increase in muscle responsiveness (31) (32) (33) .
In our findings, a close relationship between the bron chial inflammation and the AHR was demostrated. That is, the peak of the airway inflammation was shown at 12 24 hr after the last antigenic challenge and the peak of the AHR was shown at 24 hr after the last challenge. When dogs inhaled ozone, a close association was ob served between the development of AHR and an acute inflammatory response in the airways, as measured by an influx of neutrophils into the epithelial and sub-epithelial layers of the airways (34) and bronchoalveolar fluid (35) . Furthermore, in other animal preparations such as rab bits (36) , guinea pigs (37) and even in humans (38) , airway inflammation had also occurred at the same time as the de velopment of AHR. Gibson et al. (39) reported that stable asthmatic individuals who were subjected to the provoca tion test with allergen inhalation demonstrated an in creased histamine airway responsiveness at 24 hr after the provocation, accompanied by airway inflammation. Their results are in good accordance with ours in terms of 
